目的 探討復(fù)方斑蝥膠囊聯(lián)合卡培他濱片治療晚期結(jié)直腸癌的臨床療效。方法 選取2014年1月-2016年12月在南京鼓樓醫(yī)院集團(tuán)宿遷市人民醫(yī)院進(jìn)行治療的晚期結(jié)直腸癌患者60例為研究對(duì)象，入組者依據(jù)用藥的差別分為對(duì)照組和治療組，每組各30例。對(duì)照組口服卡培他濱片，1 250 mg/m²，2次/d，治療2周，停藥1周，3周為1個(gè)療程。治療組在對(duì)照組基礎(chǔ)上口服復(fù)方斑蝥膠囊，0.75 g/次，2次/d，3周為1個(gè)療程。兩組均治療3個(gè)療程。觀察兩組的臨床療效，比較兩組的腫瘤標(biāo)志物、生命質(zhì)量測(cè)定量表（QLQ-C30）評(píng)分和毒副反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組的有效率（ORR）分別為23.33%、50.00%，臨床受益率（CBR）分別為53.33%、86.67%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清癌胚抗原（CEA）、糖類抗原糖鏈抗原199（CA199）、糖類抗原糖鏈抗原242（CA242）水平顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組軀體、認(rèn)知、情緒、角色和社會(huì)功能評(píng)分顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對(duì)照組和治療組毒副反應(yīng)發(fā)生率分別為66.67%、40.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方斑蝥膠囊聯(lián)合卡培他濱片治療晚期結(jié)直腸癌具有較好的臨床療效，可改善患者生存質(zhì)量，降低腫瘤標(biāo)志物水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Compound Banmao Capsules combined with Capecitabine Tablets in treatment of advanced colorectal cancer. Methods Patients (60 cases) with advanced colorectal cancer in Suqian People's Hospital of Nanjing Gulou Hospital Group from January 2014 to December 2016 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Capecitabine Tablets, 1 250 mg/m², twice daily, treated for 2 weeks, 3 weeks as a course of treatment. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 0.3 g/time, twice daily, 3 weeks as a course of treatment. Patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and tumor markers, QLQ-C30 scores, toxicity and side effects in two groups were compared. Results After treatment, the clinical efficacies (ORR) in the control and treatment groups were 23.33% and 50.00%, respectively, and the clinical benefit rate (CBR) in the control and treatment groups were 53.33% and 86.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CEA, CA199, and CA242 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the scores of body, cognition, emotion, role, and social function in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). The incidence rates of toxicity and side effects in the control and treatment groups were 66.67% and 40.00%, respectively, and there was difference between two groups (P<0.05). Conclusion Compound Banmao Capsules combined with Capecitabine Tablets has clinical curative effect in treatment of advanced colorectal cancer, can improve the quality of life, and decrease the level of tumor markers, with good safety, which has a certain clinical application value.